cholestyramine resin has been researched along with ezetimibe in 18 studies
| Studies (cholestyramine resin) | Trials (cholestyramine resin) | Recent Studies (post-2010) (cholestyramine resin) | Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) |
|---|---|---|---|---|---|
| 2,669 | 342 | 190 | 2,484 | 563 | 1,465 |
| Protein | Taxonomy | cholestyramine resin (IC50) | ezetimibe (IC50) |
|---|---|---|---|
| NPC1-like intracellular cholesterol transporter 1 | Homo sapiens (human) | 0.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, WV | 1 |
| Gylling, H; Miettinen, TA; Vanhanen, H | 1 |
| Kane, JP; Malloy, MJ; Pullinger, CR | 1 |
| Nash, DT | 1 |
| Clark, LT | 1 |
| Ballantyne, CM; Chiou, P; Guyton, JR; Jones, PH; Stein, JL; Xydakis, AM | 1 |
| Charlotte, N; Sani, M | 1 |
| Alton, KB; Bergman, AJ; Johnson-Levonas, AO; Kosoglou, T; Paolini, JF; Statkevich, P | 1 |
| Skottová, N; Sobolová, L; Urbánek, K; Vecera, R | 1 |
| Balbisi, EA | 1 |
| Patel, SB; Salen, G; Sisk, CM; Starc, T | 1 |
| Hussain, SA | 1 |
| Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ | 1 |
| Plans-Rubió, P | 1 |
| Aoki, I; Bakalova, R; Hadjidekov, G; Ishii, I; Kitada, M; Saga, T; Tomizawa, A; Zhelev, Z | 1 |
| Annema, W; Blum, D; Mary, JL; Maugeais, C; Tietge, UJ | 1 |
| Herbas, MS; Ishida, N; Kume, A; Shichiri, M; Suzuki, H | 1 |
| Cai, T; Can, A; Castro, VM; Dligach, D; Du, R; Finan, S; Gainer, V; Murphy, S; Savova, G; Shadick, NA; Weiss, ST; Yu, S | 1 |
7 review(s) available for cholestyramine resin and ezetimibe
| Article | Year |
|---|---|
Therapies on the horizon for cholesterol reduction.
Topics: Acetamides; Acetates; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholestyramine Resin; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxysteroid Dehydrogenases; Hypercholesterolemia; Membrane Glycoproteins; Pyrimidines; Rosuvastatin Calcium; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2001 |
[Combination therapy of hypercholesterolemia].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Margarine; Phytosterols | 2002 |
Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Diet, Fat-Restricted; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL | 2003 |
Optimizing lipid lowering in patients at risk.
Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Risk Assessment | 2004 |
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Availability; Cholestyramine Resin; Contraceptives, Oral; Drug Interactions; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Warfarin | 2005 |
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors | 2006 |
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome | 2010 |
11 other study(ies) available for cholestyramine resin and ezetimibe
| Article | Year |
|---|---|
A statin for a patient with hyperlipidemia and hepatitis C?
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholestyramine Resin; Diet; Exercise; Ezetimibe; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Risk Factors | 2004 |
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Colesevelam Hydrochloride; Colestipol; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Risk Factors; Treatment Outcome | 2004 |
Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats.
Topics: Animals; Antioxidants; Azetidines; Cholesterol, Dietary; Cholestyramine Resin; Ezetimibe; Flavonoids; Intestinal Absorption; Lipoproteins; Lipoproteins, VLDL; Liver; Male; Phenols; Polyphenols; Rats; Silymarin; Triglycerides | 2006 |
Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis.
Topics: Anticholesteremic Agents; Azetidines; Child; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Risk Assessment; Severity of Illness Index; Sitosterols; Treatment Outcome; Xanthomatosis | 2006 |
Effect of melatonin on cholesterol absorption in rats.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholestyramine Resin; Ezetimibe; Intestinal Absorption; Liver; Male; Melatonin; Rats; Rats, Sprague-Dawley | 2007 |
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
Topics: Azetidines; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Drugs, Generic; Ezetimibe; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Spain; Time Factors | 2010 |
Nitroxide derivatives for imaging of hypercholesterolemia-induced kidney dysfunction and assessing the effectiveness of antilipidemic drugs.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Contrast Media; Cyclic N-Oxides; Drug Monitoring; Ezetimibe; Gadolinium DTPA; Humans; Hypercholesterolemia; Kidney; Kinetics; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Nitrogen Oxides; Pyrrolidines; Renal Insufficiency | 2011 |
rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; Azetidines; Bile Acids and Salts; Biological Transport; Cholesterol, HDL; Cholestyramine Resin; Drug Synergism; Ezetimibe; Feces; Intestinal Absorption; Liver; Macrophages; Mice; Mice, Inbred C57BL; Models, Biological; Sterols; Triglycerides | 2013 |
Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection.
Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Antimalarials; Berberine; Cholestyramine Resin; Ezetimibe; Female; Malaria; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parasitemia; Plasmodium yoelii; Probucol; Specific Pathogen-Free Organisms; Vitamin E Deficiency | 2016 |
Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture.
Topics: Adult; Aged; Aneurysm, Ruptured; Benzimidazoles; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Intracranial Aneurysm; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligonucleotides; PCSK9 Inhibitors; Propensity Score; Protective Factors | 2018 |